{"id":1209,"date":"2023-07-12T16:20:19","date_gmt":"2023-07-12T14:20:19","guid":{"rendered":"https:\/\/centrosviluppofarmaci-opbg.it\/trial\/ni-0501-14\/"},"modified":"2023-07-12T16:20:19","modified_gmt":"2023-07-12T14:20:19","slug":"ni-0501-14","status":"finished","type":"trial","link":"https:\/\/centrosviluppofarmaci-opbg.it\/en\/trial\/ni-0501-14\/","title":{"rendered":"NI-0501-14"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">A Two-cohort, Open-label, Single-arm, Multicenter Study to Evaluate Efficacy, Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of Emapalumab in Children and Adults with Macrophage Activation Syndrome (MAS) in Still\u2019s Disease (Including Systemic Juvenile Idiopathic Arthritis and Adult Onset Still\u2019s Disease) or with MAS in Systemic Lupus Erythematosus<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A Two-cohort, Open-label, Single-arm, Multicenter Study to Evaluate Efficacy, Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of Emapalumab in Children and Adults with Macrophage Activation Syndrome (MAS) in Still\u2019s Disease (Including Systemic Juvenile Idiopathic Arthritis and Adult Onset Still\u2019s Disease) or with MAS in Systemic Lupus Erythematosus<\/p>\n","protected":false},"author":3,"featured_media":0,"menu_order":0,"template":"","meta":{"footnotes":""},"trials_category":[],"scope":[49],"class_list":["post-1209","trial","type-trial","status-finished","hentry","scope-rheumatology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>NI-0501-14 - Centro Sviluppo Farmaci<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/centrosviluppofarmaci-opbg.it\/en\/trial\/ni-0501-14\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NI-0501-14 - Centro Sviluppo Farmaci\" \/>\n<meta property=\"og:description\" content=\"A Two-cohort, Open-label, Single-arm, Multicenter Study to Evaluate Efficacy, Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of Emapalumab in Children and Adults with Macrophage Activation Syndrome (MAS) in Still\u2019s Disease (Including Systemic Juvenile Idiopathic Arthritis and Adult Onset Still\u2019s Disease) or with MAS in Systemic Lupus Erythematosus\" \/>\n<meta property=\"og:url\" content=\"https:\/\/centrosviluppofarmaci-opbg.it\/en\/trial\/ni-0501-14\/\" \/>\n<meta property=\"og:site_name\" content=\"Centro Sviluppo Farmaci\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/centrosviluppofarmaci-opbg.it\\\/en\\\/trial\\\/ni-0501-14\\\/\",\"url\":\"https:\\\/\\\/centrosviluppofarmaci-opbg.it\\\/en\\\/trial\\\/ni-0501-14\\\/\",\"name\":\"NI-0501-14 - Centro Sviluppo Farmaci\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/centrosviluppofarmaci-opbg.it\\\/en\\\/#website\"},\"datePublished\":\"2023-07-12T14:20:19+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/centrosviluppofarmaci-opbg.it\\\/en\\\/trial\\\/ni-0501-14\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/centrosviluppofarmaci-opbg.it\\\/en\\\/trial\\\/ni-0501-14\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/centrosviluppofarmaci-opbg.it\\\/en\\\/trial\\\/ni-0501-14\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/centrosviluppofarmaci-opbg.it\\\/en\\\/homepage\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NI-0501-14\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/centrosviluppofarmaci-opbg.it\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/centrosviluppofarmaci-opbg.it\\\/en\\\/\",\"name\":\"Centro Sviluppo Farmaci\",\"description\":\"Insieme, facciamo crescere l\u2019innovazione.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/centrosviluppofarmaci-opbg.it\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NI-0501-14 - Centro Sviluppo Farmaci","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/centrosviluppofarmaci-opbg.it\/en\/trial\/ni-0501-14\/","og_locale":"en_US","og_type":"article","og_title":"NI-0501-14 - Centro Sviluppo Farmaci","og_description":"A Two-cohort, Open-label, Single-arm, Multicenter Study to Evaluate Efficacy, Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of Emapalumab in Children and Adults with Macrophage Activation Syndrome (MAS) in Still\u2019s Disease (Including Systemic Juvenile Idiopathic Arthritis and Adult Onset Still\u2019s Disease) or with MAS in Systemic Lupus Erythematosus","og_url":"https:\/\/centrosviluppofarmaci-opbg.it\/en\/trial\/ni-0501-14\/","og_site_name":"Centro Sviluppo Farmaci","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/centrosviluppofarmaci-opbg.it\/en\/trial\/ni-0501-14\/","url":"https:\/\/centrosviluppofarmaci-opbg.it\/en\/trial\/ni-0501-14\/","name":"NI-0501-14 - Centro Sviluppo Farmaci","isPartOf":{"@id":"https:\/\/centrosviluppofarmaci-opbg.it\/en\/#website"},"datePublished":"2023-07-12T14:20:19+00:00","breadcrumb":{"@id":"https:\/\/centrosviluppofarmaci-opbg.it\/en\/trial\/ni-0501-14\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/centrosviluppofarmaci-opbg.it\/en\/trial\/ni-0501-14\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/centrosviluppofarmaci-opbg.it\/en\/trial\/ni-0501-14\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/centrosviluppofarmaci-opbg.it\/en\/homepage\/"},{"@type":"ListItem","position":2,"name":"NI-0501-14"}]},{"@type":"WebSite","@id":"https:\/\/centrosviluppofarmaci-opbg.it\/en\/#website","url":"https:\/\/centrosviluppofarmaci-opbg.it\/en\/","name":"Centro Sviluppo Farmaci","description":"Insieme, facciamo crescere l\u2019innovazione.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/centrosviluppofarmaci-opbg.it\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"related_news":null},"card_html":"\n<div class=\"card card-trial\">\n    <div class=\"card-body\">\n        <h4 class=\"card-title\">NI-0501-14<\/h4>\n        <p>A Two-cohort, Open-label, Single-arm, Multicenter Study to Evaluate Efficacy, Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of Emapalumab in Children and Adults with Macrophage Activation Syndrome (MAS) in Still\u2019s Disease (Including Systemic Juvenile Idiopathic Arthritis and Adult Onset Still\u2019s Disease) or with MAS in Systemic Lupus Erythematosus<\/p>\n                <a href=\"https:\/\/centrosviluppofarmaci-opbg.it\/en\/trial\/ni-0501-14\/\" title=\"Show more\" class=\"link-secondary\">\n            <svg class=\"icon\"><use xlink:href=\"https:\/\/centrosviluppofarmaci-opbg.it\/wp-content\/themes\/csf\/assets\/dist\/svg\/sprite-icon.svg#icon-arrow-right\"><\/use><\/svg>\n        <\/a>\n    <\/div>\n    <div class=\"card-footer d-grid gap-2\">\n\t    \t            <button class=\"btn btn-outline-secondary\" data-bs-toggle=\"modal\" data-bs-target=\"#contactIModal\" data-bs-trial=\"NI-0501-14\">\n\t\t    Contact us for information        <\/button>\n\t        <\/div>\n<\/div>\n","_links":{"self":[{"href":"https:\/\/centrosviluppofarmaci-opbg.it\/en\/wp-json\/wp\/v2\/trial\/1209","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/centrosviluppofarmaci-opbg.it\/en\/wp-json\/wp\/v2\/trial"}],"about":[{"href":"https:\/\/centrosviluppofarmaci-opbg.it\/en\/wp-json\/wp\/v2\/types\/trial"}],"author":[{"embeddable":true,"href":"https:\/\/centrosviluppofarmaci-opbg.it\/en\/wp-json\/wp\/v2\/users\/3"}],"version-history":[{"count":0,"href":"https:\/\/centrosviluppofarmaci-opbg.it\/en\/wp-json\/wp\/v2\/trial\/1209\/revisions"}],"wp:attachment":[{"href":"https:\/\/centrosviluppofarmaci-opbg.it\/en\/wp-json\/wp\/v2\/media?parent=1209"}],"wp:term":[{"taxonomy":"trials_category","embeddable":true,"href":"https:\/\/centrosviluppofarmaci-opbg.it\/en\/wp-json\/wp\/v2\/trials_category?post=1209"},{"taxonomy":"scope","embeddable":true,"href":"https:\/\/centrosviluppofarmaci-opbg.it\/en\/wp-json\/wp\/v2\/scope?post=1209"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}